Introduction
Last updated 24 October 2026. Two commission-earning providers publish a current bremelanotide (PT-141) injection price. PlexusDx is $189 month to month. The same page lists $159 a month on a 12-month plan billed as $1,908 up front.
RxSpan MD's public product API lists PT-141 (injection) at $199 with a month price unit. PlexusDx says compounded medications are not approved by the FDA. The RxSpan API does not print that sentence. The catalog records the RxSpan row as compounded.
Two injection prices, opened 24 October 2026
Bremelanotide is sold here under the name PT-141. The commission-earning catalog has more than two PT-141 rows, but only two had a full injection price that could be read on 24 October 2026. PlexusDx publishes the plan ladder on its PT-141 page. RxSpan MD publishes one visible API row named PT-141 (injection) at 199 with price unit Month.
A from-price checked before this date is not in that pair. Bodybuilding Health+ is commission-earning, and the catalog stores From $169 a month for a PT-141 injection, last checked 22 August 2026. That figure is not used as a current price. Paused programs are left out. The two rows below are the prices read on 24 October 2026.
| Provider | Month-to-month | Longer plan | What the page says is included |
|---|---|---|---|
| PlexusDx | $189 | $179, $169, or $159 a month, prepaid | Provider visit, prescription, compounded PT-141, and shipping. No membership fee. compounded (not FDA-approved) |
| RxSpan MD | $199 | No longer plan on this API row | The API lists the product and the month unit. It does not itemize a visit or shipping. |
PlexusDx plan lengths
The page opened 24 October 2026 says the price depends on plan length. Month to month is $189. A 3-month plan is $179 a month, $537 billed up front. A 6-month plan is $169 a month, $1,014 billed up front. A 12-month plan is $159 a month, $1,908 billed up front. The 3-, 6-, and 12-month plans are charged once, up front, and renew automatically. The page says future renewals can be cancelled anytime, and that those longer plans can also be paid over time when checkout shows that option. It also says there is no membership fee, and that one price covers the provider visit, the prescription, the medication, and shipping.
The catalog row checked 21 September 2026 said $189 a month flat, with no commitment tiers. That sentence is no longer the page. The month-to-month dollar is still $189. The new fact is the prepaid ladder. The page says the provider sets the dose and the schedule. This note does not restate a dose.
| Plan | Per month | Due up front |
|---|---|---|
| Month to month | $189 | Billed monthly |
| 3 months | $179 | $537 |
| 6 months | $169 | $1,014 |
| 12 months | $159 | $1,908 |
RxSpan MD's API row
The product API opened 24 October 2026 returned one visible item named PT-141 (injection). The price field is 199 and the price unit is Month. The description says medications are issued only when clinically appropriate after a provider evaluation, and that RXspan MD does not manufacture compounded medications. It does not say whether this row is compounded, and it does not print an FDA-approval sentence. The Telehealth Ledger catalog already records the row as compounded injection, and the dollar matches the API.
The same API is the catalog source for RxSpan's GLP-1 prices. A category page that says no products were found does not replace an API row that is marked visible. No 3-month, 6-month, or 12-month PT-141 row appeared in that response.
A combination tablet with a from-price
Shed sells Desire, a sublingual tablet the page describes as oxytocin and bremelanotide. That is not the injection row above. The page opened 24 October 2026 prints From $56.33/mo in the footer and says compounded medications are not FDA-approved. The fetched text does not print $169, and it does not say what plan length produces $56.33. A from-price is a floor, not the later monthly bill.
The catalog row checked 14 September 2026 said from $56.33 a month, billed $169 every 3 months. This note does not carry that $169 forward, because it was not in the text opened 24 October 2026. Shed is commission-earning. The visit still belongs on the provider page. The injection comparison stays PlexusDx and RxSpan MD.
From $56.33/mo is not a second injection price, and it is not the low of the $189 to $199 pair.
Compounded status, in the pages' own words
PlexusDx's PT-141 page says compounded medications are not approved by the FDA and are not reviewed for quality, safety, or efficacy. Shed's Desire page says compounded medications are not FDA-approved and are prepared by a licensed pharmacy based on a provider's prescription. Those sentences are about the products on those pages. They are not a statement that a particular reader should or should not use one.
RxSpan's API does not print the FDA sentence. The catalog label for that row is compounded, which is a classification in this catalog, not a sentence from the API. This note does not call any of the three products a generic, and it does not compare them with an FDA-approved bremelanotide brand. The dose, the schedule, and whether a prescription is appropriate are decisions for the licensed provider. The side-effect and eligibility note already on this site is the evidence page. This page is the price.
A compounded drug is not FDA-approved. A monthly price is not a claim about effect.
Common questions
- How much does bremelanotide cost in 2026?
- On 24 October 2026, PlexusDx lists compounded PT-141 at $189 month to month. RxSpan MD's product API lists PT-141 (injection) at $199 with a month price unit. PlexusDx's 12-month plan is $159 a month, billed as $1,908 up front.
- Is $159 the monthly price?
- It is the per-month figure on PlexusDx's 12-month plan. The page says that plan is $1,908 billed up front. The month-to-month price on the same page is $189. The 3-month and 6-month plans are $179 and $169 a month, also billed up front.
- Did PlexusDx used to charge one flat price?
- The catalog checked 21 September 2026 recorded $189 a month flat, with no commitment tiers. The page opened 24 October 2026 still has $189 month to month and adds the prepaid tiers. The flat-price sentence is not the current page.
- Does Shed sell PT-141 for $56.33?
- The Desire page opened 24 October 2026 prints From $56.33/mo for a tablet of oxytocin and bremelanotide. It does not print the plan length for that floor, and it does not print $169. That tablet is not the $189 or $199 injection row.
- Is compounded PT-141 FDA-approved?
- PlexusDx and Shed say the compounded medication on their pages is not FDA-approved. RxSpan's API does not print that sentence. The catalog records the RxSpan row as compounded. This note does not call any of them a generic.
Use the month-to-month injection price, then the plan term
On 24 October 2026, PlexusDx compounded PT-141 is $189 month to month, and RxSpan MD lists PT-141 injection at $199 a month. PlexusDx's $159 figure is a 12-month plan billed as $1,908 up front. Shed's From $56.33/mo is a combination tablet and a floor. PlexusDx and Shed say the compounded product is not FDA-approved.
Sources
- PlexusDx PT-141 pagePlexusDx · Accessed 24 October 2026
Opened 24 October 2026. PT-141 (bremelanotide) injection is $189 month to month, $179 a month for 3 months ($537 up front), $169 a month for 6 months ($1,014 up front), and $159 a month for 12 months ($1,908 up front). The longer plans are charged once, up front, and renew automatically. The page says future renewals can be cancelled anytime, and that those plans can also be paid over time when checkout shows that option. One price covers the provider visit, prescription, compounded PT-141, and shipping. No membership fee. The page says compounded medications are not approved by the FDA. The catalog sentence from 21 September 2026, $189 flat with no commitment tiers, is not the current page.
- RxSpan MD product API, PT-141 injectionRxSpan MD · Accessed 24 October 2026
Opened 24 October 2026. One visible product is named PT-141 (injection), price 199, price unit Month. The description says medications are issued when clinically appropriate and that RXspan MD does not manufacture compounded medications. It does not print an FDA-approval sentence. The catalog records the row as compounded.
- Shed Desire pageShed Rx · Accessed 24 October 2026
Opened 24 October 2026. Desire is a sublingual tablet of oxytocin and bremelanotide. The page prints From $56.33/mo and says compounded medications are not FDA-approved. The fetched text does not print $169 or a 3-month total. The catalog row checked 14 September 2026 said from $56.33 a month billed $169 every 3 months. That billing term was not on the text opened 24 October 2026.
- Bodybuilding Health+ homepage, catalog sourceBodybuilding Health+ · Accessed 22 August 2026
Catalog checked 22 August 2026. PT-141 injection is stored as From $169 a month. That check is older than 24 October 2026, so this note does not use $169 as a current price. The provider is commission-earning.
Refresh triggers
- PlexusDx PT-141 plan price or prepaid term change
- RxSpan MD API price or price unit for PT-141 (injection)
- Shed Desire page printing a plan length or a dollar other than the from-price